Summary
The contribution of atrial natriuretic peptide (ANP) to the development of glomerular hyperfiltration in diabetes was investigated by examining the effects of HS-142-1, a non-peptide antagonist of biological receptors for ANP, on glomerular filtration rate (GFR) and renal plasma flow (RPF) in rats with streptozotocin-induced diabetes. Three to four weeks after streptozotocin injection, the plasma concentration of ANP, urinary cyclic GMP excretion rate, GFR, and RPF were significantly higher in diabetic rats than in control rats. The increase in GFR and RPF in diabetic rats was significantly reduced, in a dose-dependent manner, by a single intravenous injection of HS-142-1; the maximal effect was apparent at a dose of 10 mg per kg of body weight. Continuous subcutaneous administration of HS-142-1 with an osmotic minipump for 3 to 4 weeks, beginning 2 days after streptozotocin injection, prevented the increases in urinary cyclic GMP excretion rate, GFR, and RPF observed in untreated diabetic rats. These results highlight the importance of ANP in the development of diabetic glomerular hyperfiltration and indicate that this condition can be prevented by continuous inhibition of the action of ANP.
Article PDF
Similar content being viewed by others
Abbreviations
- ANP:
-
Atrial natriuretic peptide
- GFR:
-
glomerular filtration rate
- RPF:
-
renal plasma flow
- PAH:
-
para-aminohippurate
References
Mogensen CE, Andersen MJF (1975) Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalization by insulin-treatment. Diabetologia 11: 221–224
Christiansen JS, Gammelgaard J, Frandsen M, Parving H-H (1981) Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetics. Diabetologia 20: 451–456
Hostetter TH, Troy JL, Brenner BM (1981) Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19: 410–415
Jensen PK, Christiansen JS, Steven K, Parving H-H (1981) Renal function in streptozotocin-diabetic rats. Diabetologia 21: 409–414
Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311: 89–93
Hostetter TH, Rennke HG, Brenner BM (1982) The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72: 375–380
Ortola FV, Ballermann BJ, Anderson S, Mendez RE, Brenner BM (1987) Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest 80: 670–674
Perico N, Benigni A, Gabanelli M et al. (1992) Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats. Diabetes 41: 533–538
Morishita Y, Takahashi M, Sano T et al. (1991) Isolation and purification of HS-142-1, a novel nonpeptide antagonist for the atrial natriuretic peptide receptor, from Aureobasidium sp. Agric Biol Chem 55: 3017–3025
Morishita Y, Sano T, Kase H, Yamada K, Inagami T, Matsuda Y (1992) HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist, blocks ANP-induced renal responses through a specific interaction with guanylyl cyclase-linked receptors. Eur J Pharmacol 225: 203–207
Tanaka T, Ichimura M, Nakajo S et al. (1992) HS-142-1, a novel non-peptide antagonist for atrial natriuretic peptide receptor, selectively inhibits particulate guanylyl cyclase and lowers cyclic GMP in LLC-PK1 cells. Biosci Biotech Biochem 56: 1041–1045
Haneda M, Kikkawa R, Koyo D et al. (1993) Biological receptors mediate anti-proliferative action of atrial natriuretic peptide in cultured mesangial cells. Biochem. Biophys Res Commun 192: 642–648
Kikkawa R, Haneda M, Sakamoto K et al. (1993) Antagonist for atrial natriuretic peptide receptors ameliorates glomerular hyperfiltration in diabetic rats. Biochem Biophys Res Commun 193: 700–705
Lang RE, Tholken H, Ganten D, Luft FC, Ruskoaho H, Unger T (1985) Atrial natriuretic factor — a circulating hormone stimulated by volume loading. Nature 314: 264–266
Waugh WH (1977) Photometry of inulin and polyfructosan by use of a cysteine/tryptophan reaction. Clin Chem 23: 639–645
Dalton RN, Wiseman MJ, Turner C, Viberti G (1988) Measurement of urinary para-aminohippuric acid in glycosuric diabetics. Kidney Int 34: 117–120
Wong KR, Xie M-H, Shi L-B et al. (1988) Urinary cGMP as biological marker of the renal activity of atrial natriuretic factor. Am J Physiol 255: F1220-F1224
Huang C-L, Ives HE, Cogan MG (1986) In vivo evidence that cGMP is the second messenger for atrial natriuretic factor. Proc Natl Acad Sci USA 83: 8015–8018
Hebden RA, Todd ME, McNeill JH (1989) Relationship between atrial granularity and release of atrial natriuretic factor in rats with diabetes mellitus. Am J Physiol 257: R932-R938
Todd ME, Hebden RA, Gowen B, Tang C, McNeill JH (1990) Atrial structure and plasma ANF levels in rats with chronic diabetes mellitus. Diabetes 39: 483–489
Okwueze MI, Opgenorth TJ, Geldern TWV, Vari RC (1994) Atrial natriuretic peptide and glomerular hyperfiltration during onset of spontaneous diabetes mellitus. Am J Physiol 266: R572-R577
Sawicki PT, Heinemann L, Rave K, Hohmann A, Berger M (1988) Atrial natriuretic factor in various stages of diabetic nephropathy. J Diabetic Complications 2: 207–209
Bell GM, Bernstein RK, Laragh JH, Atlas SA, James GD, Pecker MS et al. (1989) Increased plasma atrial natriuretic factor and reduced plasma renin in patients with poorly controlled diabetes mellitus. Clin Sci 77: 177–182
Predel HG, Schulte-Vels O, Sorger M, Glanzer K, Geller C, Kramer HJ (1990) Atrial natriuretic peptide in patients with diabetes mellitus type I. Am J Hypertens 3: 674–681
Smits P, Hersbach FMRJ, Jansen TLTA, Thien T, Lutterman JA (1993) Impaired vasodilator response to atrial natriuretic factor in IDDM. Diabetes 42: 1454–1461
Maack T (1992) Receptors of atrial natriuretic factor. Annu Rev Physiol 54: 11–27
Sano T, Morishita Y, Yamada K, Matsuda Y (1992) Effects of HS-142-1, a novel non-peptide ANP antagonist, on diuresis and natriuresis induced by acute volume expansion in anesthetized rats. Biochem Biophys Res Commun 182: 824–829
Sano T, Morishita Y, Matsuda Y, Yamada K (1992) Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin. I. Selective inhibition of the actions of natriuretic peptides in anesthetized rats. J Pharmacol Exp Ther 260: 825–831
Awazu M, Imada T, Kon V, Inagami T, Ichikawa I (1989) Role of endogenous atrial natriuretic peptide in congestive heart failure. Am J Physiol 257: R641-R646
Christlieb AR, Long R, Underwood RH (1979) Reninangiotensin-aldosterone system, electrolyte homeostasis and blood pressure in alloxan diabetes. Am J Med Sci 277: 295–303
Hebden RA, Gardiner SM, Bennett T, MacDonald IA (1986) The influence of streptozotocin-induced diabetes mellitus on fluid and electrolyte handling in rats. Clin Sci 70: 111–117
Zatz R, Meyer TW, Rennke HG, Brenner BM (1985) Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82: 5963–5967
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sakamoto, K., Kikkawa, R., Haneda, M. et al. Prevention of glomerular hyperfiltration in rats with streptozotocin-induced diabetes by an atrial natriuretic peptide receptor antagonist. Diabetologia 38, 536–542 (1995). https://doi.org/10.1007/BF00400721
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00400721